Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Account Payables (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Change in Account Payables data on record, last reported at $275000.0 in Q4 2025.

  • For Q4 2025, Change in Account Payables fell 81.32% year-over-year to $275000.0; the TTM value through Dec 2025 reached $580000.0, up 103.04%, while the annual FY2025 figure was $580000.0, 103.04% up from the prior year.
  • Change in Account Payables reached $275000.0 in Q4 2025 per AMLX's latest filing, up from -$33000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $15.8 million in Q4 2023 and bottomed at -$18.4 million in Q3 2023.
  • Average Change in Account Payables over 5 years is -$5800.0, with a median of $61500.0 recorded in 2021.
  • Peak YoY movement for Change in Account Payables: soared 2736.16% in 2022, then crashed 1570.57% in 2023.
  • A 5-year view of Change in Account Payables shows it stood at $1.4 million in 2021, then plummeted by 157.72% to -$800000.0 in 2022, then surged by 2077.5% to $15.8 million in 2023, then crashed by 90.7% to $1.5 million in 2024, then crashed by 81.32% to $275000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $275000.0 in Q4 2025, -$33000.0 in Q3 2025, and -$1.5 million in Q2 2025.